Lead Product(s): GBP510
Therapeutic Area: Infections and Infectious Diseases Product Name: GBP510
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Deal Size: $210.1 million Upfront Cash: Undisclosed
Deal Type: Funding May 24, 2021
Funding will support Phase 3 trials of SK bioscience’s recombinant protein vaccine candidate (GBP510) and adaptation for use against multiple variants of concern.